Pharmacogenetics of P450 oxidoreductase: Effect of sequence variants on activities of CYP1A2 and CYP2C19

Pharmacogenetics and Genomics

Volumn 18, Issue 7, 2008, Pages 569-576

  Agrawal, Vishal ^a   Huang, Ningwu ^a   Miller, Walter L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antley Bixler syndrome; Cytochrome P450; Drug metabolism; Enzymology; Mutations; Steroidogenesis

Indexed keywords

CYTOCHROME C; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 REDUCTASE; CYP1A2 PROTEIN, HUMAN; CYP2C19 PROTEIN, HUMAN; MUTANT PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; UNSPECIFIC MONOOXYGENASE;

ALLELE; ARTICLE; BACTERIUM; CATALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME RECONSTITUTION; GENE MUTATION; GENE SEQUENCE; HUMAN; IN VITRO STUDY; NONHUMAN; PHARMACOGENETICS; POPULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; STEROIDOGENESIS; WILD TYPE; ANIMAL; BACTERIUM TRANSFORMATION; BIOLOGICAL MODEL; CELL MEMBRANE; DRUG DETOXIFICATION; ENZYME ACTIVATION; ENZYME SPECIFICITY; ENZYMOLOGY; ESCHERICHIA COLI; GENETICS; KINETICS; METABOLISM; PHYSIOLOGY; RAT; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CATALYSIS; CELL MEMBRANE; CYTOCHROME P-450 CYP1A2; ENZYME ACTIVATION; ESCHERICHIA COLI; HUMANS; KINETICS; METABOLIC DETOXICATION, DRUG; MODELS, BIOLOGICAL; MUTANT PROTEINS; NADPH-FERRIHEMOPROTEIN REDUCTASE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RATS; SUBSTRATE SPECIFICITY; TRANSFORMATION, BACTERIAL;

EID: 53049088208     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32830054ac     Document Type: Article

References (52)

1. Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, Nebert DW. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 2004; 14:1-18.
2. Guengerich FP. Cytochrome P450: what have we learned and what are the future issues? Drug Metab Rev 2004; 36:159-197.
3. Miller WL. Regulation of steroidogenesis by electron transfer. Endocrinology 2005; 146:2544-2550.
4. Hubbard PA, Shen AL, Paschke R, Kasper CB, Kim JJ. NADPH-cytochrome P450 oxidoreductase. Structural basis for hydride and electron transfer. J Biol Chem 2001; 276:29163-29170.
5. Masters BSS. The journey from NADPH-cytochrome P450 oxidoreductase to nitric oxide synthases. Biochem Biophys Res Commun 2005; 338:507-519.
6. Scott RR, Gomes LG, Huang N, Van Vliet G, Miller WL. Apparent manifesting heterozygosity in P450 oxidoreductase deficiency and its effect on coexisting 21-hydroxylase deficiency. J Clin Endocrinol Metab 2007; 92:2318-2322.
7. Wang M, Roberts DL, Paschke R, Shea TM, Masters BSS, Kim JJP. Three-dimensional structure of NADPH-cytochrome P450 reductase: prototype for FMN- and FAD-containing enzymes. Proc Natl Acad Sci U S A 1997; 94:8411-8416.
8. Shen AL, O'Leary KA, Kasper CB. Association of multiple developmental defects and embryonic lethality with loss of microsomal NADPH-cytochrome P450 oxidoreductase. J Biol Chem 2002; 277:6536-6541.
9. Otto DM, Henderson CJ, Carrie D, Davey M, Gundersen TE, Blomhoff R, et al. Identification of novel roles of the P450 system in early embryogenesis: effects on vasculogenesis and retinoic acid homeostasis. Mol Cell Biol 2003; 23:6103-6116.
10. Henderson CJ, Otto DM, Carrie D, Magnuson MA, McLaren AW, Rosewell I, Wolf CR. Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. J Biol Chem 2003; 278:13480-13486.
11. Wu L, Gu J, Cui HD, Zhang QY, Behr M, Fang C, et al. Transgenic mice with a hypomorphic NADPH-cytochrome P450 reductase gene: effects on development, reproduction, and microsomal cytochrome P450. J Pharm Exp Ther 2005; 312:35-43.
12. Ribes V, Otto DM, Dickmann L, Schmidt K, Schuhbaur B, Henderson C, et al. Rescue of cytochrome P450 oxidoreductase (POR) mouse mutants reveals functions in vasculogenesis, brain and limb patterning linked to retinoic acid homeostasis. Dev Biol 2007; 303:66-81.
13. Flück CE, Tajima T, Pandey AV, Arlt W, Okuhara K, Verge CF, et al. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet 2004; 36:228-230.
14. Adachi M, Tachibana K, Asakura Y, Yamamoto T, Hanaki K, Oka A. Compound heterozygous mutation of cytochrome P450 oxidoreductase gene (POR) in two patients with Antley-Bixler syndrome. Am J Med Genet 2004; 128A:333-339.
15. Arlt W, Walker EA, Draper N, Ivison HE, Ridle JP, Hammer F, et al. Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet 2004; 363:2128-2135.
16. Huang N, Pandey AV, Agrawal V, Reardon W, Lapunzina PD, Mowat D, et al. Diversity and function of mutations in P450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am J Hum Genet 2005; 76:729-749.
17. Fukami M, Horikawa R, Nagai T, Tanaka T, Naiki Y, Sato N, et al. Cytochrome P450 oxidoreductase gene mutations and Antley-Bixler syndrome with abnormal genitalia and/or impaired steroidogenesis: molecular and clinical studies in 10 patients. J Clin Endocrinol Metab 2005; 90:414-426.
18. Fukami M, Hasegawa T, Horikawa R, Ohashi T, Nishimura G, Homma K, Ogata T. Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res 2006; 59:276-280.
19. DeLozier CD, Antley RM,Williams R, Green N, Heller RM, Bixler D, Engel E. The syndrome of multisynostotic osteodysgenesis with long-bone fractures. Am J Med Genet 1980; 7:391-403.
20. Crisponi G, Porcu C, Piu ME. Antley-Bixler syndrome: case report and review of the literature. Clin Dysmorphol 1997; 6:61-68.
21. Scott RR, Miller WL. Genetic and clinical features of P450 oxidoreductase deficiency. Hormone Res 2008; 69:266-275.
22. Lu AY, Junk KW, Coon MJ. Resolution of the cytochrome P450-containing α-hydroxylation system of liver microsomes into three components. J Biol Chem 1969; 244:3714-3721.
23. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med 2006; 57:119-137.
24. Roden DM, Altman RB, Benowitz NL, Flockhart DA, Giacomini KM, Johnson JA, et al. Pharmacogenomics: challenges and opportunities. Ann Intern Med 2006; 145:749-757.
25. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286:487-491.
26. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 2004; 429:464-468.
27. Ingelman-Sundberg M. The human genome project and novel aspects of cytochrome P450 research. Toxicol Appl Pharmacol 2005; 207:S52-S56.
28. Cascorbi I. Genetic basis of toxic reactions to drugs and chemicals. Toxicol Lett 2006; 162:16-28.
29. Giacomini KM, Brett CM, Altman RB, Benowitz NL, Dolan ME, Flockhart DA, et al. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther 2007; 81:328-345.
30. Yengi LG, Leung L, Kao J. The evolving role of drug metabolism in drug discovery and development. Pharm Res 2007; 24:842-858.
31. Huang N, Agrawal V, Giacomini KM, Miller WL. Genetics of P450 oxidoreductase. Sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc Natl Acad Sci U S A 2008; 105:1733-1738.
32. Dierks EA, Davis SC, Ortiz de Montellano PR. Glu-320 and Asp-323 are determinants of the CYP4A1 hydroxylation regiospecificity and resistance to inactivation by 1-aminobenzotriazole. Biochemistry 1998; 37:1839-1847.
33. Miroux B,Walker JE. Over-production of proteins in Escherichia coli: mutant hosts that allow synthesis of some membrane proteins and globular proteins at high levels. J Mol Biol 1996; 260:289-298.
34. Saribas AS, Gruenke L, Waskell L. Overexpression and purification of the membrane-bound cytochrome P450 2B4. Protein Exp Purif 2001; 21:303-309.
35. Cheng D, Kelley RW, Cawley GF, Backes WL. High-level expression of recombinant rabbit cytochrome P450 2E1 in Escherichia coli C41 and its purification. Protein Exp Purif 2004; 33:66-71.
36. Marks BD, Smith RW, Braun HA, Goossens TA, Christenson M, Ozers MS, et al. A high throughput screening assay to screen for CYP2E1 metabolism and inhibition using a fluorogenic vivid P450 substrate. Assay Drug Dev Tech 2002; 1:73-81.
37. Backes WL, Kelley RW. Organization of multiple cytochrome P450s with NADPH-cytochrome P450 reductase in membranes. Pharmacol Ther 2003; 98:221-233.
38. Trubetskoy OV, Gibson JR, Marks BD. Highly miniaturized formats for in vitro drug metabolism assays using vivid fluorescent substrates and recombinant human cytochrome P450 enzymes. J Biomol Screen 2005; 10:56-66.
39. Sandhu P, Guo Z, Baba T, Martin MV, Tukey RH, Guengerich FP. Expression of modified human cytochrome P450 1A2 in Escherichia coli: stabilization, purification, spectral characterization, and catalytic activities of the enzyme. Arch Biochem Biophys 1994; 309:168-177.
40. Marohnic CC, Panda SP, Martasek P, Masters BS. Diminished FAD binding in the Y459H and V492E Antley-Bixler syndrome mutants of human cytochrome P450 reductase. J Biol Chem 2006; 281:35975-35982.
41. Miwa GT, Lu AY. The association of cytochrome P-450 and NADPHcytochrome P-450 reductase in phospholipid membranes. Arch Biochem Biophys 1984; 234:161-166.
42. Yamazaki H, Nakamura M, Komatsu T, Ohyama K, Hatanaka N, Asahi S, et al. Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. Protein Exp Purif 2002; 24:329-337.
43. Gonzalez FJ, Tuckey RC. Drug metabolism. In: Brunton L, Lazo J, Parker K, editors. Goodman & Gilman's the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill (Medical Publishing Division); 2006. pp. 71-91.
44. Testa B, Kramer SD. The biochemistry of drug metabolism: an introduction: part 1. Principles and overview. Chem Biodivers 2006; 3:1053-1101.
45. Testa B, Kramer SD. The biochemistry of drug metabolism: an introduction: part 2. Redox reactions and their enzymes. Chem Biodivers 2007; 4:257-405.
46. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 2004; 25:193-200.
47. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 2002; 34:83-448.
48. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997; 32:210-258.
49. Hart SN, Wang S, Nakamoto K, Wesselman C, Li Y, Zhong XB. Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism. Pharmacogenet Genomics 2008; 18:11-24.
50. Pandey AV, Kempna P, Hofer G, Mullis PE, Flück CE. Modulation of human CYP19A1 activity by mutant NADPH P450 oxidoreductase. Mol Endocrinol 2007; 21:2579-2593.
51. Dhir V, Ivison HE, Krone N, Shackleton CHL, Doherty AJ, Stewart PM, Arlt W. Differential inhibition of CYP17A1 and CYP21A2 activities by the P450 oxidoreductase mutant A287P. Mol Endocrinol 2007; 21:1958-1968.
52. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. J Am Med Assoc 2001; 286:2270-2279.